Caplin Point Laboratories financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹610cr+19.6% on Q1 FY26
Net profit
₹179cr+18.8% on Q1 FY26
EBITDA margin
35.0%+0.1 pts on Q1 FY26
EPS
₹23.27+15.8% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue610510+19.6%
EBITDA213178+20.1%
EBITDA margin35.0%34.8%+0.1 pts
Profit before tax225184+22.1%
Net profit179151+18.8%
EPS₹23.27₹20.10+15.8%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹610 crNet profit₹179 crNet margin29.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
17,957————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
480480511377337
44.444.435.931.126.8
0.60.60.61.23.4
17,522————
2,2872,1871,9371,6941,467
—+12.9%+14.4%+15.5%—
797761647551441
34.8%34.8%33.4%32.6%30.1%
718688581498396
678650541461377
29.6%29.7%27.9%27.2%25.7%
₹87.55₹84.37₹74.13₹60.14₹49.51
—+13.8%+23.3%+21.5%—
—523432311272
—−248−192−146−194
27527524116577.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAPLIPOINT₹2,362.80

Caplin Point Laboratories Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMERISGLANDBLUEJETCONCORDBIOACUTAASEMCUREGRANULESMcap ₹17,957 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————17,957.3
- Cash, Equiv & ST Investments336.7376.7510.8479.9479.9
+ Minority Interest26.831.135.944.444.4
+ Total Debt3.41.20.60.60.6
Enterprise Value————17,522.3
Revenue1,466.71,694.11,937.52,187.22,287.3
Growth %, YoY—+15.5+14.4+12.9—
EBITDA441.1551.4646.9760.9796.6
Margin %30.0732.5533.3934.7934.83
EBIT396.1498.0581.0688.1718.5
Net Income377.0461.4541.1649.7678.1
Margin %25.7027.2427.9329.7129.64
EPS, Adj (current shares)49.5160.1474.1384.3787.55
Growth %, YoY—+21.5+23.3+13.8—
Cash from Operations271.7311.0432.4523.2—
Capital Expenditures-193.8-145.8-191.5-248.1—
Free Cash Flow77.9165.2240.9275.1275.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Caplin Point Laboratories financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Caplin Point Laboratories (NSE: CAPLIPOINT) had a market capitalisation of ₹18,058 crore at the 29 October 2026 close (₹2,376.10 a share), a PE ratio of 27.1 on the last four quarters' profit and a price-to-book ratio of 5.04. In FY26 its consolidated net profit attributable to shareholders was ₹641 crore on revenue of ₹2,187 crore; in Q1 FY27 (April–June 2026) it was ₹177 crore, up 15.8% year on year. Its debt-to-equity ratio was 0.00 on 31 March 2026. Promoters held 70.57% of the shares on 30 September 2026.

Share price used
₹2,376.10 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Caplin Point Laboratories at a glance · consolidated

Market cap
₹18,058 Crat ₹2,376.10 · 29 Oct close
PE ratio (last 4 quarters)
27.128.2 on FY26 profit
Price to book (PB)
5.04book value ₹471.90 a share
ROE (FY26)
19.9%−1.9 pts vs FY25ROCE 21.0%
Debt to equity
0.00net cash ₹1,006 Cr
Promoter holding
70.57%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.34%₹8 a share in 12 months
Net worth
₹3,586 Cr+25.8% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹275 Cr+14.2% vs FY25

Questions

What is the Caplin Point Laboratories PE ratio today?

Caplin Point Laboratories' PE ratio is 27.1 at the 29 October 2026 close (₹2,376.10 a share): a market capitalisation of ₹18,058 crore divided by consolidated net profit attributable to shareholders of ₹665 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹641 crore) it is 28.2.

What is the Caplin Point Laboratories PB ratio (price to book value)?

Caplin Point Laboratories' price-to-book (PB) ratio is 5.04 at the 29 October 2026 close: a market capitalisation of ₹18,058 crore divided by shareholders' equity (book value) of ₹3,586 crore on 31 March 2026. That is a book value of ₹471.90 per share against a share price of ₹2,376.10.

What is the Caplin Point Laboratories net worth?

Caplin Point Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹3,586 crore on 31 March 2026, up 25.8% from ₹2,850 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹18,058 crore at the 29 October 2026 close.

What is the Caplin Point Laboratories market cap?

Caplin Point Laboratories' market capitalisation was ₹18,058 crore at the 29 October 2026 close: 7.6 crore shares at ₹2,376.10 each.

Is Caplin Point Laboratories debt free?

No. Caplin Point Laboratories had borrowings of ₹57 lakh on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.00. Its cash and current investments were ₹1,007 crore, so it held net cash of ₹1,006 crore.

What is the Caplin Point Laboratories EPS?

Caplin Point Laboratories' basic earnings per share (EPS) were ₹84.36 in FY26, against ₹70.57 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹87.53.

What is the Caplin Point Laboratories debt to equity ratio?

Caplin Point Laboratories' debt-to-equity ratio was 0.00 on 31 March 2026: borrowings of ₹57 lakh against total equity of ₹3,631 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Caplin Point Laboratories dividend in 2026 and its record date?

In 2026, Caplin Point Laboratories has declared two dividends totalling ₹8 a share: ₹4 (interim) with record date 30 May 2026 and ex-date 29 May 2026 and ₹4 with record date 18 September 2026.

What is the Caplin Point Laboratories promoter holding?

Promoters held 70.57% of Caplin Point Laboratories on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Caplin Point Laboratories ROE and ROCE?

In FY26, Caplin Point Laboratories' return on equity (ROE) was 19.9% and its return on capital employed (ROCE) was 21.0%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 21.8% and ROCE 22.1%.

What is the Caplin Point Laboratories book value per share?

Caplin Point Laboratories' book value per share was ₹471.90 on 31 March 2026: shareholders' equity of ₹3,586 crore divided by the 7.6 crore shares in issue, up 25.8% from ₹375.06 a year earlier. The share price at the 29 October 2026 close was ₹2,376.10.

What is the Caplin Point Laboratories shareholding pattern?

On 30 September 2026, Caplin Point Laboratories' shares were held by promoters 70.57%, foreign portfolio investors (FII/FPI) 5.73%, domestic institutions (DII) 2.20% (including mutual funds at 1.64%) and retail and other non-institutional investors 21.50%. Over the year, FII holding was down 0.78 percentage points from 6.51% and DII holding was up 0.10 percentage points from 2.10%.

What is the Caplin Point Laboratories dividend yield?

Caplin Point Laboratories' dividend yield is 0.34% at the 29 October 2026 close: dividends of ₹8 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹2,376.10. They were ₹4 on 18 September 2026 and ₹4 on 29 May 2026 (interim).

What is the Caplin Point Laboratories free cash flow?

In FY26, Caplin Point Laboratories generated ₹523 crore of cash from operations and spent ₹248 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹275 crore. In FY25 it was ₹241 crore.

What are the Caplin Point Laboratories latest quarterly results?

Caplin Point Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit attributable to shareholders ₹177 crore, up 15.8% from ₹153 crore in Q1 FY26; revenue from operations ₹610 crore, up 19.6% year on year.

What is the Caplin Point Laboratories revenue and profit in FY26?

In FY26 (April 2025–March 2026), Caplin Point Laboratories' consolidated net profit attributable to shareholders was ₹641 crore, up 13.8% from ₹563 crore in FY25, on revenue from operations of ₹2,187 crore (up 12.9%). Over three years, from FY23, net profit was up 70.4%.

When are the Caplin Point Laboratories next results?

Caplin Point Laboratories has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does the Caplin Point Laboratories PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Caplin Point Laboratories' PE ratio is 28.2, the third highest of the four: Ajanta Pharmaceuticals 41.1, Eris Lifesciences 26.1 and Gland Pharma 49.4, a peer average of 38.8. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Caplin Point Laboratories compare with its peers?

On FY26 consolidated figures, against Ajanta Pharmaceuticals, Eris Lifesciences and Gland Pharma: Caplin Point Laboratories' operating margin of 31.5% is the highest of the four (Ajanta Pharmaceuticals 22.4%, Eris Lifesciences 26.9%, Gland Pharma 18.8%; peer average 22.7%); its return on equity of 19.9% is the second highest of the four (Ajanta Pharmaceuticals 25.4%, Eris Lifesciences 18.3%, Gland Pharma 10.5%; peer average 18.1%); its revenue growth over three years of 14.3% a year is the third highest of the four (Ajanta Pharmaceuticals 13.4% a year, Eris Lifesciences 22.9% a year, Gland Pharma 21.1% a year; peer average 19.1% a year).

Caplin Point Laboratories vs Ajanta Pharmaceuticals: how do they compare?

In FY26, Caplin Point Laboratories earned net profit attributable to shareholders of ₹641 crore on revenue of ₹2,187 crore, against ₹1,056 crore on ₹5,453 crore for Ajanta Pharmaceuticals. Caplin Point Laboratories' operating margin was 31.5% (Ajanta Pharmaceuticals 22.4%) and its return on equity 19.9% (Ajanta Pharmaceuticals 25.4%). At the 29 October 2026 close, Caplin Point Laboratories' market capitalisation was ₹18,058 crore against ₹43,367 crore for Ajanta Pharmaceuticals, and its PE ratio on FY26 profit 28.2 against 41.1.

Where do these Caplin Point Laboratories figures come from?

From Caplin Point Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.